Bio-Techne (TECH) Curent Deferred Tax Liability (2012 - 2013)
Bio-Techne (TECH) posted quarterly Curent Deferred Tax Liability of $9.9 million for Q2 2013, down 30.14% year-over-year from $14.2 million in Q2 2012, and down 1.23% quarter-over-quarter from $10.1 million in Q1 2013.
Bio-Techne (TECH) Curent Deferred Tax Liability (2012 - 2013) Analysis & Trends
Bio-Techne's Curent Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $9.9 million for Q2 2013.
- In Q2 2013, Curent Deferred Tax Liability fell 30.14% year-over-year to $9.9 million; the TTM figure through Jun 2013 stood at $9.9 million (down 30.14% YoY), while the FY2013 annual figure was $9.9 million, down 30.14% from the prior year.
- Curent Deferred Tax Liability for Q2 2013 stood at $9.9 million, down from $10.1 million in the prior quarter.
- The five-year high for Curent Deferred Tax Liability was $14.2 million in Q2 2012, with the low at $4.2 million in Q4 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Curent Deferred Tax Liability (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Bio-Techne | 11.33 Bn | 11.12 Bn | 208.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2013 | 9.94 Mn |
| Jun 30, 2013 | 9.94 Mn |
| Mar 31, 2013 | 10.07 Mn |
| Mar 31, 2013 | 10.07 Mn |
| Dec 31, 2012 | 4.21 Mn |
| Dec 31, 2012 | 4.21 Mn |
| Sep 30, 2012 | 6.17 Mn |
| Sep 30, 2012 | 6.17 Mn |
| Jun 30, 2012 | 14.23 Mn |
| Jun 30, 2012 | 14.23 Mn |
| Mar 31, 2012 | 4.26 Mn |
| Mar 31, 2012 | 4.26 Mn |